Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 21, 2015; 21(15): 4427-4431
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4427
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4427
Treatment of esophagogastric junction carcinoma: An unsolved debate
Michele Orditura, Ferdinando De Vita, Fortunato Ciardiello, Division of Medical Oncology, Department of Internal and Experimental Medicine “F. Magrassi”, School of Medicine, Second University of Naples, 80131 Naples, Italy
Gennaro Galizia, Eva Lieto, Division of Surgical, Department of Anesthesiological, Surgical and Emergency Sciences, School of Medicine, Second University of Naples, 80131 Naples, Italy
Author contributions: All authors contributed equally to this work.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Michele Orditura, MD, PhD, Division of Medical Oncology, Department of Internal and Experimental Medicine “F. Magrassi”, School of Medicine, Second University of Naples, c/o II Policlinico, Edificio 3, Via Pansini, 5, 80131 Naples, Italy. michele.orditura@unina2.it
Telephone: +39-815-666723 Fax: +39-815-666732
Received: November 13, 2014
Peer-review started: November 15, 2014
First decision: December 26, 2014
Revised: January 2, 2015
Accepted: March 18, 2015
Article in press: March 19, 2015
Published online: April 21, 2015
Processing time: 157 Days and 16 Hours
Peer-review started: November 15, 2014
First decision: December 26, 2014
Revised: January 2, 2015
Accepted: March 18, 2015
Article in press: March 19, 2015
Published online: April 21, 2015
Processing time: 157 Days and 16 Hours
Core Tip
Core tip: Barrett’s esophagus (BE) associated with dysplasia is the main risk factor for the development of esophagogastric junction adenocarcinoma (AEG). Currently, screening programs to individuate and eradicate BE represent the best way to reduce AEG cancer. We aim to discuss several endoscopic approaches, surgical strategies for different types of AEG cancer, and multidisciplinary strategies using chemotherapy or chemoradiotherapy may improve the outcome of AEG patients.